Answers are grounded in this paper and cite their sources.
Antifungal resistance is emerging worldwide. Fluconazole resistance in Candida albicans has been steadily increasing in recent years. However, according to the World Health Organization (WHO), previous guidelines, fluconazole remains the first-line treatment for Candida infections in resource-limited settings. Here, fluconazole resistance in clinical isolates of C. albicans collected from various clinical specimens in Côte d'Ivoire was investigated, and their associated Erg11 polymorphisms were explored. Clinical samples were obtained from both outpatient and inpatient individuals at the tertiary hospital in Cocody, Abidjan. Primary yeast identification was performed by culturing on chromogenic agar and confirmed through sequencing of the ITS gene. Fluconazole minimum inhibitory concentrations (MICs) were determined following European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines. The Erg11 gene was sequenced in resistant C. albicans isolates. Positive samples included vaginal swabs (n=89), ear swabs (n=27), urine samples (n=4), oropharyngeal swabs (n=2), and buccal swabs (n=1). Molecular testing identified 52 C. albicans isolates (38.23%). Of these, six were resistant and one was intermediate (susceptible with increased exposure). All resistant and intermediate isolates had nucleotide polymorphisms in the Erg11 gene, but only two showed amino acid substitutions. C. albicans was the most frequently isolated species. Among the 52 isolates, 11.5% were resistant, with two exhibiting amino acid substitutions in Erg11. A new mutation, D116E, was detected in two resistant isolates, suggesting a potential cause of fluconazole resistance. Key words: Candida albicans, fluconazole, resistance, mutation, Erg11.
No takes yet. Share an insight, caveat, or question.
Yapi et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: